Chronic hyperaldosteronism in Cryptochrome-null mice induces high-salt-and blood pressure-independent kidney damage in mice

Hypertension Research

Volumn 37, Issue 3, 2014, Pages 202-209

  Nugrahaningsih, Dwi Aris Agung ^a   Emoto, Noriaki ^a,b   Vignon Zellweger, Nicolas ^b   Purnomo, Eko ^a   Yagi, Keiko ^b   Nakayama, Kazuhiko ^a,b   Doi, Masao ^c   Okamura, Hitoshi ^c   Hirata, Ken Ichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

aldosterone; blood pressure; kidney; salt

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALBUMIN; ALDOSTERONE; ALDOSTERONE RECEPTOR; CRYPTOCHROME; HYDRALAZINE; MINERALOCORTICOID RECEPTOR; NEPHRIN; REACTIVE OXYGEN METABOLITE; RENIN; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CREATININE CLEARANCE; GENE EXPRESSION; HISTOPATHOLOGY; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY INJURY; MALE; MOUSE; NONHUMAN; PLASMA RENIN ACTIVITY; SYSTOLIC BLOOD PRESSURE; TUBULAR DYSFUNCTION; URINALYSIS;

ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CRYPTOCHROMES; GENE EXPRESSION; GENE EXPRESSION REGULATION; HYPERALDOSTERONISM; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; REACTIVE OXYGEN SPECIES; RENIN; SODIUM CHLORIDE, DIETARY; ZONA GLOMERULOSA;

EID: 84895792795     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.143     Document Type: Article

References (44)

1. Porter GA, Edelman IS. The Action of aldosterone and related corticosteroids on sodium transport across the toad bladder. J Clin Invest 1964; 43: 611-620.
2. Connell JMC, Davies E. The new biology of aldosterone. J Endocrinol. 2005; 186: 1-20.
3. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 2008; 19: 1459-1462.
4. Fan YY, Kohno H, Hitomi H, Kitada K, Fujisawa Y, Yatabe J, Felder RA, Ohsaki H, Rafiq K, Sherajee SJ, Noma T, NIshiyama A, Nakano D. Aldosterone/mineralocorticoid receptor stimulation induces cellular senescence in the kidney. Endocrinology 2011; 152: 680-688.
5. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159-172.
6. Greene EL, Kren S, Hotetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068.
7. Iwazu Y, Muto S, Fujisawa G, Nakazawa E, Okada K, Ishibasi S, Kusano E. Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/salt-induced tubulointerstitial fibrosis. Hypertension 2008; 51: 749-754.
8. Blasi ER, Rocha R, Rudolp AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation in hypertensive rats. Kidney Int 2003; 63: 1791-1800.
9. Krammer AB, van der Meulen EF, Hamming I, van Goor H, Navis G. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 2007; 71: 417-424.
10. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878.
11. Queisser N, Amann K, Hey V, Habib SL, Schupp N. Blood pressure has only minor influence on aldosterone-induced oxidative stress and DNA damage in vivo. Free Radic Biol Med 2013; 54: 17-25.
12. Klanke B, Cordasic N, Hartner A, Schmieder RE, Veelken R, Hilgers KF. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. Nephrol Dial Transplant 2008; 23: 3456-3463.
13. Brem AS, Morris DJ, Ge Y, Dworkin L, Tolbert E, Gong R. Direct fibrogenic effects of aldosterone on normotensive kidney: an effect modified by 11-HSD activity. Am J Physiol Renal Physiol 2010; 298: F1178-F1187.
14. Sancar A. Regulation of the mammalian circardian clock by cryptochrome. J Biol Chem 2004; 279: 34079-34082.
15. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G, Kanematsu A, Ogawa O, Todo T, Tsutsui K, van der Horst GT, Okamura H. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med 2010; 16: 67-74.
16. Vitaterna MH, Selby CP, Todo T, Niwa H, Thompson C, Fruechte EM, Hitomo K, Thresher RJ, Ishikawa T, Miyazaki J, Takahashi JS, Sancar A. Differential regulation of mammalian period genes and circardian rhythmicity by cryptochromes 1 and 2. Proc Natl Acad Sci USA 1999; 96: 12114-12119.
17. Fan H, Yang HC, You L, Wang YY, He WJ, Hao CM. The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion- induced acute kidney injury. Kidney Int 2013; 83: 404-413.
18. Takagi N, Tanizawa T, Kon V, Fogo AB, Ichikawa I, Ma J. Mineralocorticoid receptor blocker protects against podocyte-dependent glomerulosclerosis. Nephron Extra 2012; 2: 17-26.
19. Funder JW. Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone. Hypertension 2006; 47: 634-635.
20. Matsunaga M, Hara A, Song TS, Hashimoto M, Tamori S, Ogawa K, Morimoto K, Pak CH, Kawai C, Yoshida O. Asymptomatic normotensive primary aldosteronism: case report. Hypertension 1983; 2: 240-243.
21. Nishimiya T, Kikuchi K, Oimatsu H, Ota S, Nakamura Y, Shimamoto K, Iimura O. A case of normotensive primary aldosteronism-comparison with 13 previously experienced cases with hypertension. Endocrinal Jpn 1984; 2: 159-164.
22. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859.
23. Shargorodsky M, Zimlichman R. Primary aldosteronism: the most frequent form of secondary hypertension. Isr Med Assoc J 2002; 4: 32-33.
24. Lombès M, Farman N, Oblin ME, Baulieu EE, Bonvalet JP, Erlanger BF, Gasc JM. Immunohistochemical localization of renal mineralocorticoid receptor by using an anti-idiotypic antibody that is an internal image of aldosterone. Proc Natl Acad Sci USA 1990; 87: 1086-1088.
25. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, Nagai Y, Nakamura E, Yoshizumi M, Shokoji T, Kimura S, Kiyomoto H, Tsujioka K, Kohno M, Tamaki T, Kajiya F, Abe Y. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005; 45: 710-716.
26. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and sgk1. Hypertension 2007; 49: 355-364.
27. Ruotsalainen V, Ljungberg P, Wartiovaara J, Lenkkeri U, Kestila M, Jalanko H, Holmberg C, Tryggvason K. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. PNAS 1999; 96: 7962-7967.
28. Xu Y, Zhang Z, Hu J, Stillman IE, Leopold JA, Handy DE, Loscalzo J, Stanton RC. Glucose-6-phosphate dehydrogenase-deficient mice have increased renal oxidative stress and increased albuminuria. FA SE B J 2010; 24: 609-616.
29. Yoshida K, Kim-Mitsuyama S, Wake R, Izumiya Y, Yukimura T, Ueda M, Yoshiyama M, Iwao H. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 2005; 28: 447-455.
30. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehy-drogenase activity. Nat Med 2007; 13: 189-197.
31. Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab 2009: 1191-1197.
32. Kok KY, Yapp SK. Laparoscopic adrenal sparing surgery for primary hyperaldsteronism due to aldosterone producing adenoma. Surg Endosc 2002; 1: 108-1011.
33. Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endress S, Beuschlein F, Willenberg HS, Rump LC, Allolio B, Reincke M, Quinkler MMephisto Study Group. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol 2012; 168: 75-81.
34. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-2645.
35. Catena C, Colussi GL, Sechi AL. Kidney in primary aldosteronism: key determinant of treatment outcome. World J Hypertens 2012; 2: 1-6.
36. Sanders PW, Gibbs CL, Akhi KM, MacMillan-Crow LA, Zinn KR, Chen YF, Young CJ, Thompson JA. Increased dietary salt accelerates chronic allograft nephropathy in rats. Kidney Int 2001; 59: 1149-1157.
37. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007; 50: 877-883.
38. Kreutz R, Kovacevic L, Schulz A, Rothermund L, Ketteler M, Paul M. Effect of high NaCl diet on spontaneous hypertension in a genetic rat model with reduced nephron number. J Hypertens 2000; 18: 777-782.
39. Kawarazaki H, Ando K, Shibata S, Muraoka K, Fujita M, Kawarasaki C, Fujita T. Mineralocorticoid receptor-Rac1 activation and oxidative stress play major roles in salt induced hypertension and kidney injury in prepubertal rats. J Hypertens 2012; 30: 1977-1985.
40. Shibata S, Mu S, Karawazaki H, Muraoka K, Ishizawa K, Yoshida S, Kawarazaki W, Takeuchi M, Ayuzawa N, Miyoshi J, Takai Y, Ishikawa A, Shimosawa T, Ando K, Nagase M, Fujita T. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor dependent pathway. J Clin Invest 2011; 121: 3233-3243.
41. Luther JM, Luo P, Wang Z, Cohen SE, Kim HS, Fogo AB, Brown NJ. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal and vascular injury. Kidney Int 2012; 82: 643-651.
42. Ebeiqbe AB, Aloamaka CP. Mechanism of hydralazine-induced relaxation of arterial smooth muscle. Cardiovasc Res 1985; 19: 400-405.
43. Wilkinson EL, Backman H, Hecht HH. Cardiovascular and renal adjustment to hypotensive agents. Circulation 1952; 31: 872-879.
44. Cogen JJ, Humphreys MH, Carlson CJ, Rapaport E. Renal effects of nitroprusside and hydralazine in patients with congestive heart failure. Circulation 1980; 61: 316-323.